

Leandro Cerchietti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7472017/publications.pdf>

Version: 2024-02-01

118
papers

6,701
citations

70961

41
h-index

64668

79
g-index

122
all docs

122
docs citations

122
times ranked

10652
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692. | 7.7 | 706 |
| 2 | Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8368-8373. | 3.3 | 286 |
| 3 | Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. <i>Nature Medicine</i> , 2004, 10, 1329-1335. | 15.2 | 272 |
| 4 | A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. <i>Cancer Cell</i> , 2010, 17, 400-411. | 7.7 | 263 |
| 5 | Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , 2011, 7, 818-826. | 3.9 | 240 |
| 6 | The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401. | 13.7 | 233 |
| 7 | MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo. <i>Cancer Cell</i> , 2012, 22, 812-824. | 7.7 | 229 |
| 8 | The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548. | 0.6 | 205 |
| 9 | Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. <i>Cancer Discovery</i> , 2013, 3, 1002-1019. | 7.7 | 180 |
| 10 | BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR/ABL1 kinase inhibition. <i>Nature</i> , 2011, 473, 384-388. | 13.7 | 174 |
| 11 | The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. <i>Nature</i> , 2014, 511, 90-93. | 13.7 | 168 |
| 12 | A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters. <i>Cell Reports</i> , 2013, 4, 578-588. | 2.9 | 161 |
| 13 | BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 2163-2174. | 4.2 | 154 |
| 14 | A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6 dependent B cell lymphomas. <i>Nature Medicine</i> , 2009, 15, 1369-1376. | 15.2 | 149 |
| 15 | Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer. <i>Molecular Cell</i> , 2008, 29, 384-391. | 4.5 | 144 |
| 16 | DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89. | 0.6 | 138 |
| 17 | Limits in the detection of m6A changes using MeRIP/m6A-seq. <i>Scientific Reports</i> , 2020, 10, 6590. | 1.6 | 136 |
| 18 | Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3351-3362. | 3.9 | 133 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Histone deacetylase inhibitor treatment induces β -BRCAness TM and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. <i>Oncotarget</i> , 2014, 5, 5637-5650. | 0.8 | 131 |
| 20 | Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3207-3212. | 3.3 | 130 |
| 21 | DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , 2011, 118, 3559-3569. | 0.6 | 123 |
| 22 | Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021, 11, 1468-1489. | 7.7 | 119 |
| 23 | The Bcl6-SMRT/NCOR Cistrome Represses Inflammation to Attenuate Atherosclerosis. <i>Cell Metabolism</i> , 2012, 15, 554-562. | 7.2 | 111 |
| 24 | Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921. | 5.8 | 111 |
| 25 | BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , 2010, 207, 1209-1221. | 4.2 | 108 |
| 26 | Ex Vivo engineered immune organoids for controlled germinal center reactions. <i>Biomaterials</i> , 2015, 63, 24-34. | 5.7 | 108 |
| 27 | Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137. | 1.5 | 102 |
| 28 | MiR-592 Regulates the Induction and Cell Death-Promoting Activity of p75 ^{NTR} in Neuronal Ischemic Injury. <i>Journal of Neuroscience</i> , 2014, 34, 3419-3428. | 1.7 | 82 |
| 29 | Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , 2016, 127, 858-868. | 0.6 | 76 |
| 30 | Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , 2013, 121, 5192-5202. | 0.6 | 75 |
| 31 | Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. <i>Nature Genetics</i> , 2017, 49, 866-875. | 9.4 | 75 |
| 32 | Integrin α _v β ₃ acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. <i>Blood</i> , 2015, 125, 841-851. | 0.6 | 74 |
| 33 | THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. <i>Nature Communications</i> , 2017, 8, 14290. | 5.8 | 74 |
| 34 | Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. <i>Cancer Cell</i> , 2019, 35, 916-931.e9. | 7.7 | 70 |
| 35 | Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. <i>Biomaterials</i> , 2015, 73, 110-119. | 5.7 | 66 |
| 36 | Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2020, 30, 755-770.e6. | 2.9 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. <i>Blood</i> , 2013, 122, 2837-2847. | 0.6 | 64 |
| 38 | Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. <i>Blood</i> , 2011, 118, 4174-4178. | 0.6 | 58 |
| 39 | Germline Lysine-Specific Demethylase 1 (<i>LSD1/KDM1A</i>) Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018, 78, 2747-2759. | 0.4 | 56 |
| 40 | Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 192-196. | 0.2 | 53 |
| 41 | Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas. <i>PLoS ONE</i> , 2011, 6, e18436. | 1.1 | 45 |
| 42 | BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. <i>Cancer Discovery</i> , 2017, 7, 506-521. | 7.7 | 43 |
| 43 | Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. <i>Cellular and Molecular Bioengineering</i> , 2014, 7, 394-408. | 1.0 | 37 |
| 44 | Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4559-4571. | 3.9 | 37 |
| 45 | Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. <i>Cancer Research</i> , 2017, 77, 3070-3081. | 0.4 | 36 |
| 46 | Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. <i>Clinical Epigenetics</i> , 2016, 8, 79. | 1.8 | 35 |
| 47 | BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 295-295. | 0.6 | 34 |
| 48 | BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. <i>Cancer Discovery</i> , 2019, 9, 662-679. | 7.7 | 31 |
| 49 | The eukaryotic translation initiation factor eIF4E elevates steady-state m ⁷ G capping of coding and noncoding transcripts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26773-26783. | 3.3 | 29 |
| 50 | Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. <i>Breast Cancer Research</i> , 2014, 16, 491. | 2.2 | 27 |
| 51 | Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 3520-3532. | 0.8 | 26 |
| 52 | Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. <i>EBioMedicine</i> , 2018, 28, 80-89. | 2.7 | 25 |
| 53 | Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer. <i>ACS Chemical Biology</i> , 2014, 9, 1698-1705. | 1.6 | 23 |
| 54 | Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner. <i>Journal of Biomedical Materials Research - Part A</i> , 2017, 105, 1833-1844. | 2.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , 2013, 122, 1-1. | 0.6 | 23 |
| 56 | Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. <i>Oncotarget</i> , 2016, 7, 79637-79653. | 0.8 | 21 |
| 57 | The metabolism of lymphomas. <i>Current Opinion in Hematology</i> , 2013, 20, 345-354. | 1.2 | 19 |
| 58 | Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 591-595. | 0.9 | 19 |
| 59 | The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases. <i>Science Advances</i> , 2021, 7, eabg1964. | 4.7 | 18 |
| 60 | Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. <i>Expert Review of Hematology</i> , 2013, 6, 343-345. | 1.0 | 17 |
| 61 | Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159. | 0.6 | 17 |
| 62 | Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216. | 0.4 | 14 |
| 63 | Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. <i>Blood Cancer Discovery</i> , 2022, 3, 50-65. | 2.6 | 14 |
| 64 | Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. <i>Cancer Research</i> , 2017, 77, 1818-1830. | 0.4 | 13 |
| 65 | High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells. <i>Cancer Letters</i> , 2015, 368, 97-104. | 3.2 | 12 |
| 66 | A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603. | 1.7 | 11 |
| 67 | Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. <i>Blood</i> , 2011, 118, 3725-3725. | 0.6 | 11 |
| 68 | Variational autoencoders learn transferrable representations of metabolomics data. <i>Communications Biology</i> , 2022, 5, . | 2.0 | 11 |
| 69 | ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. <i>Blood</i> , 2009, 114, 619-619. | 0.6 | 10 |
| 70 | SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75Åyears or older with newly diagnosed aggressive non-Hodgkin lymphomas â€“ Aiming to improve therapy, outcomes, and validate a prospective frailty tool. <i>Journal of Geriatric Oncology</i> , 2022, 13, 258-264. | 0.5 | 9 |
| 71 | Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2020, 10, 13094. | 1.6 | 8 |
| 72 | Design and Development of Small Molecules for Specific Targeted Therapy of Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2007, 110, 799-799. | 0.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | DNA Methylation-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2017, 35, 793-795. | 0.8 | 7 |
| 74 | The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. <i>Leukemia and Lymphoma</i> , 2018, 59, 256-258. | 0.6 | 7 |
| 75 | Thyroid hormones induce doxorubicin chemosensitivity through enzymes involved in chemotherapy metabolism in lymphoma T cells. <i>Oncotarget</i> , 2019, 10, 3051-3065. | 0.8 | 7 |
| 76 | Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. <i>Blood</i> , 2019, 134, 656-656. | 0.6 | 6 |
| 77 | The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. <i>Blood</i> , 2013, 122, 781-781. | 0.6 | 6 |
| 78 | Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. <i>Cell Cycle</i> , 2016, 15, 2241-2247. | 1.3 | 5 |
| 79 | Histamine H4 Receptor Agonism Induces Antitumor Effects in Human T-Cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1378. | 1.8 | 5 |
| 80 | Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2688-2693. | 1.1 | 4 |
| 81 | Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). <i>Blood</i> , 2018, 132, 2964-2964. | 0.6 | 4 |
| 82 | BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 446-446. | 0.6 | 4 |
| 83 | Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. <i>Haematologica</i> , 2021, , . | 1.7 | 3 |
| 84 | Specific Peptide Disruption of the Bcl-6 Repression Complex Reveals Its Transcriptional Mechanism of Action in Normal and Malignant B-Cells and Is a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 5-5. | 0.6 | 3 |
| 85 | BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain. <i>Blood</i> , 2014, 124, 567-567. | 0.6 | 3 |
| 86 | A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas. <i>Blood</i> , 2020, 136, 7-8. | 0.6 | 3 |
| 87 | Personalized Epigenetic Therapy Chemosensitivity Testing. , 2015, , 667-676. | | 2 |
| 88 | BCL6 Inhibitor Peptide Have Powerful Anti-Lymphoma Activity in Animal Models of Diffuse Large B-Cell Lymphoma and Synergize with Other Anti-Lymphoma Drugs.. <i>Blood</i> , 2006, 108, 827-827. | 0.6 | 2 |
| 89 | Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL. <i>Blood</i> , 2012, 120, 3706-3706. | 0.6 | 2 |
| 90 | Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 634-634. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | A Virtual B Cell Lymphoma Model to Predict Effective Combination Therapy. <i>Blood</i> , 2014, 124, 928-928. | 0.6 | 2 |
| 92 | BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2167-2167. | 0.6 | 2 |
| 93 | <i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. <i>Cancer Discovery</i> , 0, , OF1-OF20. | 7.7 | 2 |
| 94 | Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 218-221. | 0.6 | 1 |
| 95 | DNA Methyltransferase 1 Contributes to Epigenetic Signatures and Biological Phenotype during Normal B-Cell Differentiation and Lymphomagenesis.. <i>Blood</i> , 2007, 110, 685-685. | 0.6 | 1 |
| 96 | BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 202-202. | 0.6 | 1 |
| 97 | Connectivity Mapping of BCL6 Targeted Therapy Guides Rational Design of Potent and Specific Non-Chemotherapy Combinatorial Regimens in DLBCL.. <i>Blood</i> , 2007, 110, 523-523. | 0.6 | 1 |
| 98 | BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.. <i>Blood</i> , 2009, 114, 91-91. | 0.6 | 1 |
| 99 | Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 64-64. | 0.6 | 1 |
| 100 | Serum Metabolomics Uncovers a New Therapeutic Target in Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2012, 120, 1648-1648. | 0.6 | 1 |
| 101 | Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. <i>Blood</i> , 2014, 124, 1764-1764. | 0.6 | 1 |
| 102 | Sensitivity of Diffuse Large B-Cell Lymphomas to DNA Methyltransferase Inhibitors Is Associated with a Specific Epigenetic Signature.. <i>Blood</i> , 2006, 108, 831-831. | 0.6 | 0 |
| 103 | BCL6 Regulates Diffuse Large B-Cell Lymphoma Cell Cycle and Apoptosis Checkpoints through Direct Repression of the p300 Histone Acetyl-Transferase.. <i>Blood</i> , 2006, 108, 1413-1413. | 0.6 | 0 |
| 104 | A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 616-616. | 0.6 | 0 |
| 105 | Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma. <i>Blood</i> , 2008, 112, 602-602. | 0.6 | 0 |
| 106 | BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2009, 114, 765-765. | 0.6 | 0 |
| 107 | STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. <i>Blood</i> , 2010, 116, 705-705. | 0.6 | 0 |
| 108 | Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , 2011, 118, 1617-1617. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. Blood, 2011, 118, 1406-1406. | 0.6 | 0 |
| 110 | Thyroid Hormones Maintain The CTCL Malignant Phenotype Through Membrane- and Nuclear-Initiated Transcriptional Programs. Blood, 2013, 122, 3810-3810. | 0.6 | 0 |
| 111 | A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. Blood, 2013, 122, 821-821. | 0.6 | 0 |
| 112 | Unbiased Pharmacological Screening Identified New Therapeutic Strategies For Peripheral T-Cell Lymphomas (PTCLs). Blood, 2013, 122, 4423-4423. | 0.6 | 0 |
| 113 | Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL. Blood, 2013, 122, 4339-4339. | 0.6 | 0 |
| 114 | Integrin $\alpha 5 \beta 3$ Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target. Blood, 2014, 124, 510-510. | 0.6 | 0 |
| 115 | Transcription Regulation Targeting in Peripheral T Cell Lymphomas Induces Apoptosis and Sensitization to BCL2 Inhibitors. Blood, 2014, 124, 810-810. | 0.6 | 0 |
| 116 | HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. Blood, 2017, 130, 645-645. | 0.6 | 0 |
| 117 | Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. Blood, 2018, 132, 2854-2854. | 0.6 | 0 |
| 118 | XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells. Blood, 2020, 136, 18-18. | 0.6 | 0 |